Shinya Yamanaka

Shinya Yamanaka is a Japanese physician-scientist who demonstrated in 2006 that introducing four transcription factors into an adult mouse fibroblast can return it to an embryonic-like pluripotent state, and repeated the result in human cells the following year. The four factors (Oct3/4, Sox2, Klf4 and c-Myc) are now known as the Yamanaka factors, and the cells they produce as Induced pluripotent stem cells. He shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon.

§Career

Yamanaka trained as an orthopedic surgeon at Kobe University. He has described that period as unsuccessful: he was slow in the operating theatre and found the limits of surgical repair frustrating. He moved into research and completed a doctorate in pharmacology at Osaka City University in 1993. A postdoctoral position at the Gladstone Institutes in San Francisco taught him American laboratory culture and, in his own account, the value of pursuing unexpected results: a transgenic mouse experiment aimed at cholesterol metabolism instead produced tumours, which redirected his attention to gene regulation.

Returning to Japan, he held positions at Osaka City University and the Nara Institute of Science and Technology before moving to Kyoto University in 2004. In 2010 he became the founding director of the Center for iPS Cell Research and Application (CiRA) at Kyoto, which he led until 2022; he remains a professor there, heads the associated CiRA Foundation, and retains a senior investigator position at Gladstone.

§The discovery

Gurdon had shown in the early 1960s that transferring a differentiated frog nucleus into an enucleated egg could produce a whole animal, establishing that differentiation does not delete genetic information.¹ The same principle later produced Dolly and the whole field of somatic cell nuclear transfer. It remained unknown whether the reprogramming activity resident in the egg could be reduced to a defined set of factors.

Yamanaka's group assembled twenty-four candidate genes associated with embryonic stem cell identity, introduced them together by retrovirus into mouse fibroblasts carrying a selectable pluripotency marker, and then removed genes one at a time to find the minimal set. Four sufficed.² The resulting cells formed teratomas containing all three germ layers and, in later work, contributed to chimeric mice and the germline. In 2007 the group reported the same result in human dermal fibroblasts, published within days of an independent report from James Thomson's laboratory using a partly different factor combination.³

1. 1962
   Nuclear transfer in frogs
   John Gurdon shows that a differentiated nucleus can support development, establishing that differentiation is reversible in principle.
2. 2006
   Mouse iPS cells
   Takahashi and Yamanaka narrow twenty-four candidate factors to four that reprogram mouse fibroblasts to pluripotency.
3. 2007
   Human iPS cells
   Yamanaka's group and, independently, James Thomson's group report reprogrammed human cells.
4. 2012
   Nobel Prize
   Yamanaka shares the Nobel Prize in Physiology or Medicine with Gurdon.
5. 2014
   First clinical transplant
   A Japanese team led by Masayo Takahashi transplants iPSC-derived retinal pigment epithelium into a patient with macular degeneration.

Because iPSCs require no embryo, the finding removed the political obstacle that had constrained human embryonic stem cell research in several countries. It also established that cell identity is maintained by a transcription-factor network that can be overridden. That premise later underlay Partial reprogramming and Epigenetic reprogramming as rejuvenation strategies.

§Clinical translation

CiRA's translational programme has moved deliberately. The first clinical use of iPSC-derived tissue was a retinal pigment epithelium graft for age-related macular degeneration in 2014, using cells derived from the patient's own skin.⁴ That autologous route proved too slow and too expensive to scale, and Yamanaka pushed instead for a bank of iPSC lines from donors homozygous at the major HLA loci, so that a small number of lines could be immunologically compatible with a large fraction of the Japanese population. Later work has used CRISPR–Cas9 to edit HLA genes directly, aiming at hypoimmunogenic universal lines.

Kyoto teams have since run early-phase trials of iPSC-derived dopaminergic progenitors for Parkinson's disease, alongside independent programmes elsewhere. Results reported in the mid-2020s have concerned safety and graft survival; some participants showed motor improvement, but there has been no controlled comparison that would establish clinical benefit. Cardiac muscle sheets, platelets and corneal epithelium have also entered early trials. Twenty years after the mouse paper, no iPSC-derived therapy is in routine clinical use. Whole organs that would address the Organ shortage remain the province of Tissue engineering and Lab-grown organs rather than of reprogramming alone.

Two uses of the same cells

Clinically, iPSCs are a source of transplantable tissue. Scientifically, they serve as patient-specific disease models and drug-screening substrates, including Organoids grown from patient cells. The second use has produced far more published results than the first, and it requires no regulatory approval.

§Caution about timelines

Unusually among the figures covered on this wiki, Yamanaka consistently argues that his own field will take longer than its advocates say. He has repeatedly cautioned that iPSC therapies face manufacturing cost, tumorigenicity and immune-rejection problems that the reprogramming step itself does not solve, and that residual undifferentiated cells in a graft are a genuine cancer risk. On rejuvenation he has been more reserved than the commercial reprogramming sector. The factors that restore pluripotency also erase cell identity, he notes, and the therapeutic window between the two is narrow and poorly characterized in vivo. A reset Epigenetic clocks reading in a reprogrammed cell shows that a measurement changed; it does not show that the tissue functions better.

He has also declined to profit personally from the discovery in the way his position would allow. Patent income goes to CiRA, and he raises research funds by running marathons, a detail often mentioned because it is so far from the norm in the sector.

§Reception and legacy

The 2006 paper is one of the most cited in modern biology, and iPSCs are now standard laboratory material. His work is also the conceptual foundation of the reprogramming-based longevity companies. Altos Labs pursues partial rather than complete factor expression in order to avoid the pluripotency Yamanaka was trying to reach, and NewLimit screens for other factor combinations that never approach it. He agreed to serve as a senior scientific adviser to Altos while remaining at Kyoto University, and he has kept the reservations described above while doing so.

The open problem he identified early has seen little progress. Reprogramming is a continuum, and nobody can yet specify how far along it a cell can be pushed to gain a younger epigenetic profile while keeping its function and not becoming a tumour. Until that dose-response relationship is characterized in vivo, claims about how close his discovery is to its most ambitious application remain assertions.

§See also

• Induced pluripotent stem cells
• Yamanaka factors
• Partial reprogramming
• Epigenetic reprogramming
• Organoids
• Human cloning
• David Sinclair
• Lab-grown organs

§References